Neurol. praxi. 2021;22(3):206-211 | DOI: 10.36290/neu.2021.040

Current treatment of brain tumours

MUDr. Jiří Polívka, CSc.1, Ing. Jiří Polívka, Ph.D.2, MUDr. Pavel Potužník1
1 Neurologická klinika, Fakultní nemocnice Plzeň a Lékařská fakulta v Plzni, Univerzita Karlova
2 Ústav histologie a embryologie a Biomedicínské centrum, Lékařská Fakulta v Plzni, Univerzita Karlova

Cancer diseases are the second leading cause of death in the Czech Republic. The incidence of primary malignant brain tumours is approximately 8/100,000 and metastatic CNS involvement is nine times higher. This article deals with new real options and perspectives of their treatment resulting from the application of oncogenesis research. It presents some classic biomarkers that have substantially changed the classification of gliomas - the largest group of primary brain tumours. Examples of essential studies are given which have changed the approach to glioma treatment. References are made to the latest EANO guidelines on the treatment of diffuse gliomas. Briefly discussed are the nature and new options of personalized immunological treatment of primary tumours as well as metastases. A model approach to the diagnosis and treatment of lymphomas is presented. Information on adverse effects of immunological cancer treatment is also provided.

Keywords: primary CNS tumours, brain metastases, novel biomarkers, integrated diagnosis, personalized cancer treatment.

Received: May 17, 2021; Revised: May 24, 2021; Accepted: May 26, 2021; Prepublished online: May 26, 2021; Published: October 1, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Polívka J, Polívka J, Potužník P. Current treatment of brain tumours. Neurol. praxi. 2021;22(3):206-211. doi: 10.36290/neu.2021.040.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bachelot T, Romieu G, Campone M, Diéras V, Cropet C, Dalenc F, Jimenez M, Le Rhun E, Pierga JY, Gonçalves A, Leheurteur M, Domont J, Gutierrez M, Curé H, Ferrero JM, Labbe-Devilliers C. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2013; 14: 64-71. https://doi.org/10.1016/S1470-2045(12)70432-1. Go to original source... Go to PubMed...
    2. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov, I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA. National Comprehensive Cancer Network. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2018; 36: 1714-1768. https://doi.org/10.1200/JCO.2017.77.6385 Go to original source... Go to PubMed...
    3. Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, Fink K, Souhami L, Laperriere N, Curran W, Mehta M. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2013; 31: 337-343. https://doi.org/10.1200/JCO.2012.43.2674 Go to original source... Go to PubMed...
    4. Chamberlain MC, Baik CS, Gadi VK, Bhatia S, Chow LQM. Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma. Neuro-Oncol. 2017; 19: i1-i24. https://doi.org/10.1093/neuonc/now197. Go to original source... Go to PubMed...
    5. Dempke WCM, Edvardsen K, Lu S, Reinmuth N, Reck M, Inoue A. Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy? Anticancer Res. 2015; 35: 5797-5806.
    6. Ferreri AJM, Holdhoff M, Nayak L, Rubenstein JL. Evolving Treatments for Primary Central Nervous System Lymphoma. Am. Soc. Clin. Oncol. Educ. Book Am. Soc. Clin. Oncol. Annu. Meet. 2019; 39:, 454-466. https://doi.org/10.1200/EDBK_242547. Go to original source... Go to PubMed...
    7. Fox BD, Cheung VJ, Patel AJ, Suki D, Rao G. Epidemiology of metastatic brain tumors. Neurosurg. Clin. N. Am. 2011; 22: 1-6, v. https://doi.org/10.1016/j.nec.2010.08.007. Go to original source... Go to PubMed...
    8. Fox CP, Phillips EH, Smith J, Linton K, Gallop-Evans E, Hemmaway C, Auer DP, Fuller C, Davies AJ, McKay P, Cwynarski, K., British Society for Haematology Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphoma. Br. J. Haematol. 2019; 184: 348-363. https://doi.org/10.1111/bjh.15661. Go to original source... Go to PubMed...
    9. Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, Tsiouris AJ, Cohen J, Vortmeyer A, Jilaveanu L, Yu J, Hegde U, Speaker S, Madura M, Ralabate A, Rivera A, Rowen E., Gerrish, H, Yao X, Chiang V, Kluger HM. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016; 17: 976-983. https://doi.org/10.1016/S1470-2045(16)30053-5. Go to original source... Go to PubMed...
    10. Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S., Larkin J, Jordan K. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann. Oncol., ESMO Updated Clinical Practice Guidelines 2017; 28: iv119-iv142. https://doi.org/10.1093/annonc/mdx225. Go to original source... Go to PubMed...
    11. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674. https://doi.org/10.1016/j.cell.2011.02.013. Go to original source... Go to PubMed...
    12. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N. Engl. J. Med. 2008; 359: 1367-1380. https://doi.org/10.1056/NEJMra0802714. Go to original source... Go to PubMed...
    13. Kiss I, a kol. n.d. Modrá kniha České onkologické společnosti, 27. aktualizace, 2021. Masarykův onkologický ústav, Brno, 978-80-86793-51-1.
    14. Kluger HM, Chiang V, Mahajan A, Zito CR, Szno, M, Tran T, Weiss SA, Cohen JV, Yu J, Hegde U, Perrotti E, Anderson G, Ralabate A, Kluger Y, Wei W, Goldberg SB, Jilaveanu LB. Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2019; 37: 52-60. https://doi.org/10.1200/JCO.18.00204. Go to original source... Go to PubMed...
    15. Komori T. The 2016 WHO Classification of Tumours of the Central Nervous System: The Major Points of Revision. Neurol. Med. Chir. (Tokyo) 2017; 57: 301-311. https://doi.org/10.2176/nmc.ra.2017-0010. Go to original source... Go to PubMed...
    16. Konecna D, Netuka D. Difuzní nízkostupňové gliomy. Ceska Slov. Neurol. Neurochir. 2020; 83: 467-488. https://doi.org/10.14735/amcsnn2020467. Go to original source...
    17. Kotecha RR, Flippot R, Nortman T, Guida A, Patil S, Escudier B, Motzer RJ, Albiges L, Voss MH. Prognosis of Incidental Brain Metastases in Patients With Advanced Renal Cell Carcinoma. J. Natl. Compr. Cancer Netw. JNCCN 2021; 19: 432-438. https://doi.org/10.6004/jnccn.2020.7634. Go to original source... Go to PubMed...
    18. Kristensen BW, Priesterbach-Ackley LP, Petersen JK, Wesseling P. Molecular pathology of tumors of the central nervous system. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2019; 30: 1265-1278. https://doi.org/10.1093/annonc/mdz164. Go to original source... Go to PubMed...
    19. Lassman AB, DeAngelis LM. Brain metastases. Neurol. Clin. 2003; 21: 1-23, vii. https://doi.org/10.1016/s0733-8619(02)00035-x. Go to original source... Go to PubMed...
    20. Le Pechoux C, Levy A. Radiosurgery in Patients With Small Cell Lung Cancer With Brain Metastases: A Call for Prospective Evidence. JAMA Oncol. 2020; 6: 1037-1038. https://doi.org/10.1001/jamaoncol.2020.1245. Go to original source... Go to PubMed...
    21. Leone, JP, Leone BA.Breast cancer brain metastases: the last frontier. Exp. Hematol. Oncol. 2015; 4: 33. https://doi.org/10.1186/s40164-015-0028-8. Go to original source... Go to PubMed...
    22. Louis DN, Aldape K, Brat DJ, Capper D, Ellison DW, Hawkins C, Paulus W, Perry A, Reifenberger G, Figarella-Branger D, Wesseling P, Batchelor TT, Cairncross JG, Pfister SM, Rutkowski S, Weller M, Wick W, von Deimling A. Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy. Acta Neuropathol. (Berl.) 2017; 133: 1-3. https://doi.org/10.1007/s00401-016-1646-x. Go to original source... Go to PubMed...
    23. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. (Berl.) 2007; 114: 97-109. https://doi.org/10.1007/s00401-007-0243-4. Go to original source... Go to PubMed...
    24. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. (Berl.) 2016; 131: 803-820. https://doi.org/10.1007/s00401-016-1545-1. Go to original source... Go to PubMed...
    25. Malmström A, Grønberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, Abacioglu U, Tavelin B, Lhermitte B, Hegi, ME, Rosell J, Henriksson R, Nordic Clinical Brain Tumour Study Group (NCBTSG). Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012; 13: 916-926. https://doi.org/10.1016/S1470-2045(12)70265-6. Go to original source... Go to PubMed...
    26. Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G. KEYNOTE-042 Investigators. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet Lond. Engl. 2019; 393: 1819-1830. https://doi.org/10.1016/S0140-6736(18)32409-7. Go to original source... Go to PubMed...
    27. Nayak L, Lee EQ, Wen PY. Epidemiology of brain metastases. Curr. Oncol. Rep. 2012; 14: 48-54. https://doi.org/10.1007/s11912-011-0203-y. Go to original source... Go to PubMed...
    28. Polivka J, Polivka J, Rohan V, Priban V. Aktuální pohled na management nízkostupňových gliových nádorů centrálního nervového systému. Ceska Slov. Neurol. Neurochir. 2016; 79: 534-540. https://doi.org/10.14735/amcsnn2016534. Go to original source...
    29. Polivka J, Polivka J, Rohan V, Priban V. Anaplastické oligodendrogliomy - nadešel čas pro personalizovanou medicínu? Ceska Slov. Neurol. Neurochir. 2014; 77: 428-434.
    30. Polivka J, Řepík T, Holubec L, Polivka J. Klasifikace nádorů centrálního nervového systému - WHO 2016 Update. Čes. Slov. Neurol. Neurochir. 2017; 80/113: 353-356. https://doi.org/10.14735/amcsnn2017353. Go to original source...
    31. Puzanov I, Diab A, Abdallah K, Bingham CO, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, Lenihan D, Onofrei C, Shannon V, Sharma R, Silk AW, Skondra D, Suarez-Almazor ME, Wang Y, Wiley K, Kaufman HL, Ernstoff MS. Society for Immunotherapy of Cancer Toxicity Management Working Group. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J. Immunother. Cancer 2017; 5: 95. https://doi.org/10.1186/s40425-017-0300-z. Go to original source... Go to PubMed...
    32. Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am. J. Pathol. 1994; 145: 1175-1190.
    33. Reveiz L, Rueda JR, Cardona AF. Chemotherapy for brain metastases from small cell lung cancer. Cochrane Database Syst. Rev. CD007464. 2012. https://doi.org/10.1002/14651858.CD007464.pub2. Go to original source... Go to PubMed...
    34. Rick JW, Shahin M, Chandra A, Dalle Ore C, Yue JK, Nguyen A, Yagnik G, Sagar S, Arfaie S, Aghi MK. Systemic therapy for brain metastases. Crit. Rev. Oncol. Hematol. 2019; 142: 44-50. https://doi.org/10.1016/j.critrevonc.2019.07.012. Go to original source... Go to PubMed...
    35. Sandru A, Voinea S, Panaitescu E, Blidaru A. Survival rates of patients with metastatic malignant melanoma. J. Med. Life 2014; 7. 572-576. Go to original source... Go to PubMed...
    36. Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O'Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely, GJ, Iyer S, Tassell V, Polli A, Wilner KD, Jänne PA. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 2013; 368: 2385-2394. https://doi.org/10.1056/NEJMoa1214886. Go to original source... Go to PubMed...
    37. Shaw EG, Wang M, Coons SW, Brachman DG, Buckner JC, Stelzer KJ, Barger, GR, Brown, PD, Gilbert MR, Mehta MP. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2012; 30: 3065-3070. https://doi.org/10.1200/JCO.2011.35.8598. Go to original source... Go to PubMed...
    38. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001; 344, 783-792. https://doi.org/10.1056/NEJM200103153441101. Go to original source... Go to PubMed...
    39. Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray, JE, Lee, SM, Hodge, R, Marotti M, Rukazenkov Y, Ramalingam SS. FLAURA Investigators. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2018; 378: 113-125. https://doi.org/10.1056/NEJMoa1713137. Go to original source... Go to PubMed...
    40. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer, RC, Ludwin, SK, Gorlia T, Allgeier A, Lacombe D, Cairncross, JG, Eisenhauer E, Mirimanoff RO. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005; 352: 987-996. https://doi.org/10.1056/NEJMoa043330. Go to original source... Go to PubMed...
    41. Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Di Meco F, Lieberman F, Zhu JJ, Stragliotto G, Tran, D., Brem, S, Hottinger A, Kirson ED, Lavy-Shahaf G, Weinber U, Kim CY, Paek SH, Nicholas G, Bruna J, Hirte H, Weller M, Palti Y, Hegi ME, Ram Z. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA 2017; 318: 2306-2316. https://doi.org/10.1001/jama.2017.18718. Go to original source... Go to PubMed...
    42. Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence. Cancers 202: 12. https://doi.org/10.3390/cancers12030738. Go to original source... Go to PubMed...
    43. van den Bent MJ. Practice changing mature results of RTOG study 9802: another positive PCV trial makes adjuvant chemotherapy part of standard of care in low-grade glioma. Neuro-Oncol. 2014; 16: 1570-1574. https://doi.org/10.1093/neuonc/nou297. Go to original source... Go to PubMed...
    44. van den Bent MJ, Brandes AA, Taphoorn MJB, Kros JM, Kouwenhoven MCM, Delattre, JY, Bernsen HJJA, Frenay M, Tijssen CC, Grisold W, Sipos L, Enting RH, French PJ, Dinjens WNM, Vecht CJ, Allgeier A, Lacombe D, Gorlia T, Hoang-Xuan K. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2013; 31: 344-350. https://doi.org/10.1200/JCO.2012.43.2229. Go to original source... Go to PubMed...
    45. von Baumgarten L, Illerhaus G, Korfel A, Schlegel U, Deckert M, Dreyling M. The Diagnosis and Treatment of Primary CNS Lymphoma. Dtsch. Arzteblatt Int. 2018; 115: 419-426. https://doi.org/10.3238/arztebl.2018.0419. Go to original source... Go to PubMed...
    46. Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G, Bendszus M, Balana C, Chinot O, Dirven L, French P, Hegi ME, Jakola AS, Platten M, Roth P, Rudà R, Short S, Smits, M, Taphoorn MJB, von Deimling A, Westphal M, Soffietti R, Reifenberger G, Wick W. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat. Rev. Clin. Oncol. 2021; 18: 170-186. https://doi.org/10.1038/s41571-020-00447-z. Go to original source... Go to PubMed...
    47. Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Combs SE, Vesper J, Braun C, Meixensberger J, Ketter R, Mayer-Steinacker R, Reifenberger G, Weller M. NOA-08 Study Group of Neuro-oncology Working Group (NOA) of German Cancer Society. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012; 13: 707-715. https://doi.org/10.1016/S1470-2045(12)70164-X. Go to original source... Go to PubMed...
    48. Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff, J., Schadendorf, D., Ferrucci, P.F., Smylie, M., Dummer, R., Hill A, Hogg D, Haanen J, Carlino MS, Bechter O, Maio M, Marquez-Rodas I, Guidoboni M, McArthur G, Lebbé C, Ascierto PA, Long GV, Cebon J, Sosman J, Postow MA, Callahan MK, Walker D, Rollin L, Bhore R, Hodi FS, Larkin J. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N. Engl. J. Med. 2017; 377: 1345-1356. https://doi.org/10.1056/NEJMoa1709684. Go to original source... Go to PubMed...
    49. Zdravotnická ročenka České republiky 2018 - ÚZIS ČR [WWW Document], n.d. URL https://www.uzis.cz/index.php?pg=record&id=8280 (accessed 3. 12. 21).

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.